

1FW

PATENT

Attorney Docket No.: 186565/US/2 Attorney File No.: 469390-00360

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

**COWAN** 

U.S. Serial No. 10/572,529

Filing Date: March 16, 2006

I.A. App. No.: PCT/US2004/030261

I.A. Filing Date: September 14, 2004

For: Methods of Screening Compositions for

G Protein-Coupled Receptor Agonist

Activity

Examiner: Not Yet Assigned

Art Unit: Not Yet Assigned

**CERTIFICATE OF MAILING** 

I hereby certify that this correspondence, including listed enclosures, is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450,

Alexandria, Virginia 22313-1450:

Dated: \_\_\_\_\_ June 13, 2006

Signed:

## INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In satisfaction of the duty of disclosure under 37 C.F.R. § 1.56, and in accordance with the provisions of 37 C.F.R. §§ 1.97 and 1.98, Applicants wish to draw the attention of the U.S. Patent and Trademark Office to the references cited on the accompanying form PTO/SB/8A. In accordance with 1287 Off. Gaz. Pat. Office 163 (October 19, 2004), no copies of U.S. patents and U.S. published applications are enclosed. Copies of foreign patents and non-patent literature, unless indicated otherwise below, are enclosed.

Further, in accordance with the provisions of 37 C.F.R. §§ 1.97(c) and 1.97(e)(1), the undersigned certifies that the references listed on the enclosed substitute for form PTO-1449 marked as reference nos. A5 and A9 were first cited in an International Search Report dated March 24, 2005, for counterpart PCT application PCT/US2004/030261. A copy of the International Search Report for the counterpart PCT application is enclosed herewith.

Serial No.: 10/572,529

Filing Date: March 16, 2006

Nothing herein shall constitute an admission concerning the contents of any of the cited references, nor shall the inclusion of a reference herein be considered an admission that the reference constitutes prior art against the invention claimed in the above-identified application. Submission of the present document shall not be construed as an admission that a search has been made or that better art does not exist.

As far as is known to the undersigned, this Information Disclosure Statement is being filed within three months of the filing date of a national application, within three months of the date of entry of the national state in an international application, or before the mailing date of a first Office Action on the merits as set forth in 37 C.F.R. § 1.97(b), and therefore no fee is required. While no fee is believed to be due, if this belief is in error, the Commissioner is authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 50-2319 (Our Order No. 469390-00360; Docket No.: 186565/US/2).

By:

Respectfully submitted,

DORSEY & WHITNEY LLP

Michael F. Kolman, Reg. No. 54,234 for

David J. Brezner, Reg. No. 24,774

Customer Number: 32940

Dorsey & Whitney LLP

555 California Street, Suite 1000 San Francisco, CA 94104-1513 Telephone: (415) 781-1989

Facsimile:

(415) 398-3249

Attachments:

Form PTO/SB/08A, substitute for Form PTO-1449

Copy of International Search Report Copies of five (5) cited references

Return Postcard

Substitute for form 1449A/PTO (Modified)

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet **1** of **1** 

Approved for use unough o//31/2008					
Complete if Known OIPE					
Application Number	10/572,529	5			
Filing Date	March 16, 2006	1111			
First Named Inventor	COWAN, Conrad L.	3 JUN 1 5 2006 **			
Art Unit	To be assigned	A LE			
Examiner Name	To be assigned	DENA			
Attorney Docket Number	186565/US/2 (469390-	00360)			

	U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.1	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Releva Passages or Relevant Figures Appea	
	A1	US-4,745,051	05-17-1988	Smith et al.		
	A2	US-4,879,236	11-07-1989	Smith et al.		
	A3	US-5,348,886	09-20-1994	Lee et al.		
	A4	US-5,625,048	04-25-1997	Tsien et al.		
	A5	US-5,707,798	01-13-1998	Brann		
	A6	US-5,731,182	03-24-1998	Boyce		
	A7	US-5,777,079	07-07-1998	Tsien et al.		
	A8	US-5,871,986	02-16-1999	Boyce		
	A9	US-5,891,646	04-06-1999	Oakley et al.		
	A10	US-6,066,476	05-23-2000	Tsien et al.		
	A11	US-6,110,693	08-29-2000	Barak et al.		
	A12	US-6,238,914 B1	05-29-2001	Boyce		
	A13	US-6,281,009 B1	08-28-2001	Boyce		
	A14	US-7,018,812 B2	03-28-2006	Oakley et al.		
	A15	US-2003-0013137 A1	01-16-2003	Barak et al.		

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code <sup>2</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)  Publication Date MM-DD-YYYY  Name of Patentee or Appli Document		Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Т <sup>6</sup>
	B1					

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No.1	No. Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposiu catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
	C1	BARAK, L., et al., "Internal trafficking and surface mobility of a functionality intact β <sub>2</sub> -adrenergic receptor-green fluorescent protein conjugate," <i>Mol. Pharmacol.</i> 51(2):177-184 (Feb. 1997).		
	C2	DREWS, J., "Drug discovery: a historical perspective," Science 287(5460):1960-1964 (Mar. 2000).		
	C3	OAKLEY, R., et al., "Differential affinities of visual arrestin, βarrestin1, βarrestin2 for G protein-coupled receptors delineate two major classes of receptors," J. Biol. Chem. 275(22):17201-17210 (Jun. 2000).		
	C4	OAKLEY, R., et al., "Molecular determinants underlying the formation of stable intracellular G protein-coupled receptor β-arrestin complexes after receptor endocytosis," <i>J. Biol. Chem.</i> 276(22):19452-19460 (Jun. 2001) (first pub'd online 03/09/2001).		
	C5	OAKLEY, R., et al., "The cellular distribution of fluorescently labeled arrestins provides a robust, sensitive, and universal assay for screening G protein-coupled receptors," Assay Drug Dev. Technol. 1(1Pt1):21-30 (Nov. 2002).		

Examiner	i c	te	
Signature	Cons	dered	
Cignatoro			

<sup>\*</sup>EXAMINER: † These references were previously cited in a related application relied upon for an earlier filling date under 35 USC 120 and no copies are submitted in accordance with 37 CFR 1.98(d). Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional).

See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04.

Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.

for possible.

Applicant is to place a check mark here if English Language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the complete application form to the USPTO. Time will vary depending on the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.